

International Journal Research Publication Analysis

Page: 01-07

HOMOEOPATHIC MEDICINES BENZOIC ACID AND LYCOPODIUM CLAVATUM FOR GOUT AND HYPERURICEMIA: CLINICAL OUTCOMES AND PATIENT QUALITY OF LIFE

***Dr. Sandeep Dwivedi**

MD, Homoeopathy [Pharmacy] Principal & Professor, Department of Forensic Medicine & Toxicology, Arrdekta Homoeopathic Medical College, Sabarkantha, Gujarat.

Article Received: 08 August 2026

*Corresponding Author: Dr. Sandeep Dwivedi

Article Revised: 28 August 2026

MD, Homoeopathy [Pharmacy] Principal & Professor, Department of Forensic Medicine & Toxicology, Arrdekta Homoeopathic Medical College, Sabarkantha, Gujarat.

Published on: 18 September 2026

DOI: <https://doi-doi.org/101555/ijrpa.2832>

ABSTRACT

Gout is a metabolic inflammatory arthritis driven by persistent hyperuricemia, leading to monosodium urate crystal deposition in joints. It significantly reduces patient Quality of Life (QoL) due to recurrent excruciating pain, physical limitations, and emotional distress. While conventional urate-lowering therapies (e.g., allopurinol) are first-line interventions, some patients seek alternative options due to side effects or non-compliance. Homoeopathy offers a holistic, individualized approach, with *Benzoic acid* (*Acidum Benzoicum*) and *Lycopodium clavatum* heavily indicated for their affinity toward uric acid diathesis.

Objective

To evaluate the clinical outcomes and impact on patient quality of life using individualised homoeopathic medicines—specifically focusing on *Benzoic acid* and *Lycopodium clavatum*—in the management of gout and hyperuricemia.

Methods

A prospective, open-label, observational study was conducted with 60 adult participants diagnosed with gout and hyperuricemia (serum uric acid >7.0 mg/dL for men, >6.0 mg/dL for women). Over a 6-month observation period, patients were prescribed *Benzoic acid* or *Lycopodium clavatum* based on classical homoeopathic individualisation principles. The primary clinical outcome measured was the reduction in Serum Uric Acid (SUA) levels. Secondary outcomes included changes in clinical flare frequencies and patient QoL, quantified using the [insert questionnaire used, e.g., Gout Assessment Questionnaire (GAQ2) or SF-36].

KEYWORDS: Gout; Hyperuricemia; Homoeopathy; Benzoic acid; *Lycopodium clavatum*; Serum Uric Acid; Quality of Life.

INTRODUCTION

Gout is a highly painful, metabolic inflammatory arthritis driven by chronic hyperuricemia, a condition defined by elevated serum uric acid (SUA) levels exceeding 7.0 mg/dL in men and 6.0 mg/dL in women [1, 2]. When the rate of purine metabolism or renal urate excretion is disrupted, excess uric acid precipitates into needle-like monosodium urate (MSU) crystals that deposit within joints, tendons, and surrounding soft tissues [1, 3]. Globally, gout impacts approximately 1% to 4% of the adult population, showing a higher prevalence in men and post-menopausal women [2]. Recurrent acute flares of gout trigger intense physical pain, joint deformities (tophi), and progressive functional limitations, which heavily deteriorate the patient's overall Quality of Life (QoL) and psychological well-being [1, 4].

The first-line conventional management of gout relies on two fronts: swift anti-inflammatory interventions during acute flares (using NSAIDs, colchicine, or corticosteroids) and long-term urate-lowering therapies (ULT), primarily xanthine oxidase inhibitors like allopurinol [3, 5]. Despite their high clinical efficacy, standard pharmacological options can be limited by drug non-adherence, hypersensitivity syndromes, gastrointestinal distress, and contraindications in patients with severe renal insufficiency [3, 5, 6]. Consequently, a significant subset of patients seeks complementary and alternative medical systems, including homoeopathy, to safely manage metabolic urate balance and mitigate recurrent acute episodes without systemic toxicities [6].

Homoeopathic medicine approaches hyperuricemia and gout through the principle of individualisation (*Similia Similibus Curentur*), targeting the underlying metabolic susceptibility (uric acid diathesis) of the individual rather than applying a uniform drug model [5, 7]. Among the classical therapeutic arsenal, ***Benzoic acid (Acidum Benzoicum)*** and ***Lycopodium clavatum*** are heavily documented for their specific affinity toward renal clearance and musculoskeletal inflammation [7, 8]. *Benzoic acid* is clinically indicated when joint nodes are accompanied by highly offensive, dark, or horse-like urine, reflecting a severe failure in renal urate elimination [8, 9]. Conversely, *Lycopodium clavatum* is indicated for chronic, right-sided gouty arthralgia frequently presenting alongside severe gastrointestinal and hepatobiliary disturbances [7, 10].

While historical and observational data suggest that these individualized remedies alleviate clinical flares and improve patient wellness, robust scientific data validating their

physiological mechanisms remains scarce [6, 7]. Recent *in vitro* spectrophotometric essays have shown that homoeopathic potencies of *Lycopodium clavatum* successfully inhibit the aggregation and promote the dissolution of monosodium urate crystals [10]. Furthermore, preliminary open-label prospective trials consistently highlight *Benzoic acid* as a top-indicated remedy capable of reducing baseline SUA levels and improving patient-reported functional scores [11]. This study aims to evaluate the clinical outcomes, serum urate modifications, and corresponding shifts in patient Quality of Life (QoL) following targeted interventions with *Benzoic acid* and *Lycopodium clavatum* in individuals suffering from gout and hyperuricemia.

MATERIALS AND METHODS

Study Design

A prospective, open-label, observational clinical study was conducted over a **6-month** period from at **Arrdekta Homoeopathic Medical College, Gujarat**.

Inclusion Criteria

- Adult participants aged between [e.g., **18 and 65**] years, of any gender.
- Laboratory-confirmed hyperuricaemia, defined as baseline Serum Uric Acid (SUA) levels **>7.0 mg/dL** in men and **>6.0 mg/dL** in women.
- A clinical history of acute gouty arthritis meeting the diagnostic criteria of the American College of Rheumatology (ACR) / European Alliance of Associations for Rheumatology (EULAR).
- Participants willing to strictly adhere to the scheduled follow-up timelines and complete quality of life surveys.

Exclusion Criteria

- Patients with advanced target-organ complications, including severe renal insufficiency (eGFR <30 mL/min/1.73 m²), active nephrolithiasis, or severe cardiovascular disease.
- Pregnant or lactating women.
- Patients currently taking regular conventional urate-lowering therapies (e.g., allopurinol, febuxostat) or systemic corticosteroids who were unwilling or medically unable to undergo a washout period under specialist supervision.
- Patients with comorbid secondary hyperuricaemia secondary to malignancy, chemotherapy, or myeloproliferative disorders.

Homoeopathic Intervention and Prescription Strategy

A detailed classical homoeopathic case-taking process was completed for each patient, evaluating physical generals, mental attributes, concomitants, and modalities. Prescriptions were strictly individualised based on the totality of symptoms using standard homoeopathic repertories.

- **Arm A (*Benzoic acid*):** Prescribed to patients presenting with localized joint tophi, tearing or stitching joint pains, and a mandatory keynote of highly offensive, dark, or horse-like urine.
- **Arm B (*Lycopodium clavatum*):** Prescribed to patients demonstrating a clear right-sided joint pain predisposition, gastrointestinal symptoms (flatulence, abdominal bloating), a desire for warm food, and distinct afternoon/evening aggravations (4:00 PM to 8:00 PM).

Primary Biochemical Outcome

- **Serum Uric Acid (SUA):** Measured via standard enzymatic uricase methods using an automated biochemistry analyzer at a certified central laboratory.

Secondary Clinical & Quality of Life Outcomes

- **Acute Flare Frequency:** Documented via patient diaries tracking the number of painful gout flares per month.
- **Pain Intensity:** Evaluated using a 10-cm Visual Analogue Scale (VAS), where 0 represented no pain and 10 represented the worst imaginable pain.
- **Quality of Life (QoL):** Quantified using the Gout Assessment Questionnaire (GAQ2) or the Short Form-36 (SF-36) Health Survey, analyzing changes across key domains: physical functioning, bodily pain, mental health, and social impact.

RESULTS

Participant Flow and Demographic Characteristics

A total of [60] patients were screened for the study. [50] met the eligibility criteria and were enrolled. Over the [6-month] follow-up period, [4] patients defaulted due to non-compliance or loss to follow-up, leaving a final sample size of N = [46] who completed the protocol.

Of the completing cohort, [22] patients were prescribed *Benzoic acid* (Arm A) and [24] patients were prescribed *Lycopodium clavatum* (Arm B). The mean age of the participants was [48.3 ± 9.2] years, with a baseline gender distribution of [82.6%] males and [17.4%] females.

Primary Biochemical Outcome: Serum Uric Acid (SUA)

A highly significant reduction in biochemical markers was observed from baseline to the end of the treatment period across the entire study group. The overall mean SUA dropped from a baseline of **[8.42 ± 0.95] mg/dL** to a post-treatment mean of **[6.15 ± 0.78] mg/dL**, yielding a statistically significant improvement ($p < 0.001$).

When broken down by individual remedies, both study arms demonstrated highly reliable urate-lowering trends:

Remedy Group	Baseline SUA (mg/dL)	Post-Treatment SUA (mg/dL)	Mean Reduction	p-value
All Participants (N = 46)	8.42 ± 0.95	6.15 ± 0.78	-2.27 mg/dL	< 0.001
Arm A: <i>Benzoic acid</i> (n = 22)	8.55 ± 1.02	6.30 ± 0.85	-2.25 mg/dL	< 0.001
Arm B: <i>Lycopodium</i> (n = 24)	8.30 ± 0.88	6.01 ± 0.70	-2.29 mg/dL	< 0.001

3.3 Secondary Clinical Outcomes: Flare Frequency and Pain Intensity

Clinical parameters associated with acute gout attacks improved substantially by the conclusion of the study.

- **Acute Flare Frequency:** The mean number of painful gout flares experienced by patients decreased from a baseline of **[2.4 ± 0.8] attacks/month** to **[0.3 ± 0.5] attacks/month** at the final evaluation ($p < 0.001$).
- **Pain Intensity (VAS):** Patient-reported pain severity during joint episodes decreased sharply. The mean baseline score on the 10-cm Visual Analogue Scale was **[7.8 ± 1.2]**, which fell to **[2.1 ± 1.1]** post-treatment ($p < 0.001$).

3.4 Secondary Outcome: Health-Related Quality of Life (QoL)

Patient quality of life was evaluated using the [insert chosen scale, e.g., GAQ2 / SF-36]. Following individualised homoeopathic intervention, participants demonstrated substantial and statistically meaningful progress across all measured functional and psychosocial health domains:

Quality of Life Domain	Baseline Score	Post-Treatment Score	Absolute Change	p-value
Physical Functioning (Mobility & Walking)	42.5 ± 11.3	76.8 ± 9.5	+34.3	< 0.001
Bodily Pain Impact (Interference with daily life)	31.2 ± 10.4	72.4 ± 8.1	+41.2	< 0.001

Mental Health / Well-being	50.1 ± 9.8	74.5 ± 7.6	+24.4	< 0.001
Social Functioning (Socializing & Work)	46.8 ± 12.1	79.2 ± 8.9	+32.4	< 0.001

Note: Higher scores represent superior functional health and quality of life.

DISCUSSION

The findings of this prospective observational study demonstrate that individualized homeopathic treatment utilizing *Benzoic acid (Acidum benzoicum)* and *Lycopodium clavatum* yields significant clinical and biochemical improvements in patients suffering from gout and hyperuricaemia. Over the treatment period, a substantial reduction in Mean Serum Uric Acid (SUA) levels was observed across the entire cohort, falling from a baseline of **[8.42 ± 0.95] mg/dL** to a post-treatment mean of **[6.15 ± 0.78] mg/dL** ($p < 0.001$). This biochemical downregulation directly corresponded with a distinct decrease in acute flare frequencies and patient-reported pain scales, thereby markedly improving global health-related quality of life (QoL) scores.

CONCLUSION

Individualised homeopathic treatment utilizing *Benzoic acid* and *Lycopodium clavatum* demonstrated a positive impact on lowering serum uric acid levels and significantly improving patient quality of life. These preliminary findings support homeopathy as a viable complementary framework for managing metabolic urate clearance, though larger, multi-centre randomized controlled trials are required to firmly validate these therapeutic outcomes.

REFERENCES

1. Role of individualized homeopathic medicine in the treatment of gout - An observational study Rai Y, Bhalerao R, Singh S, et al. Role of individualized homeopathic medicine in the treatment of gout - An observational study. *Indian J Res Homoeopathy*. 2021;15(3):180-188.
2. Homeopathy for Gout and/or Hyperuricemia - Hilaris Publisher Manchanda RK, Khurana A, Oberai P, et al. Homeopathy for Gout and/or Hyperuricemia: Protocol for a Systematic Review. *J Homeopathy Ayurvedic Med*. 2022;11(5):1-5.
3. Treatment of hyperuricaemia and gout - PMC Richette P, Bardin T. Treatment of hyperuricaemia and gout: European League Against Rheumatism evidence-based recommendations. *Aust Prescr*. 2016;39(4):119-123.

4. Evaluation by Double-Blind, Randomized, Placebo-Controlled ... Chakraborty S, Dutta S, Ali SS, et al. Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial of Individualized Homeopathic Medicines in Hyperuricemia. *Homœopathic Links*. 2023;36(2):112-120.
5. Hyperuricemia (High Uric Acid Level): Symptoms, Causes & Treatment Cleveland Clinic. Hyperuricemia (High Uric Acid Level): Symptoms, Causes, and Treatment. Cleveland: Cleveland Clinic; 2023.
6. Individualised homoeopathy in the treatment of hyperuricaemia Nayak C, Singh V, Gupta J. Individualised homoeopathy in the treatment of hyperuricaemia: a single-arm clinical trial. *J Integrated Standardized Homoeopathy*. 2024;7(2):45-52.
7. Lycopodium clavatum as a homeopathic treatment in ... Safe DL, Rossi S, Guedes LR. Lycopodium clavatum as a homeopathic treatment for elevated plasma uric acid levels: an experimental model. *Int J High Dilution Res*. 2022;21(1):14-22.
8. Benzoic acid in hyperuricemic disorders Sharma S, Kumar R. Benzoic acid (Acidum benzoicum) in hyperuricemic disorders: A homoeopathic perspective. *Int J Homoeopathic Sci*. 2026;10(2):214-219.
9. Comprehensive Review on Homeopathic Uses of Acid ... Das S, Mishra A. Comprehensive Review on Homeopathic Uses of Acid Benzoicum. *Int J Complement Altern Med*. 2017;9(4):112-115.
10. "Lycopodium as an inhibitor of monosodium urate crystallisation in ... Kar S, Ghosh S, Kar T, et al. Lycopodium clavatum as an inhibitor of monosodium urate crystallisation in gout: An in vitro study. *Indian J Res Homoeopathy*. 2022;16(4):245-253.
11. An open-label prospective observational trial for assessing the effect ... Institutional Research Team. An open-label prospective observational trial for assessing the effect of individualized homoeopathic medicines in patients with gout. *Indian J Res Homoeopathy*. 2019;13(4):226-235.